Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: A preliminary study

Clinical Orthopaedics and Related Research

Volumn 461, Issue , 2007, Pages 35-39

  Holtom, Paul D ^a   Zalavras, Charalampos G ^a   Lamp, Kenneth C ^b,c   Park, Nami ^b   Friedrich, Lawrence V ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c Cubist Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; COTRIMOXAZOLE; DAPTOMYCIN; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; ANKLE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL ARTICLE; CONFERENCE PAPER; ENTEROCOCCUS; FEMALE; FOLLOW UP; FOOT; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ARTICLE; COMORBIDITY; DIABETES MELLITUS; MICROBIOLOGY; RETROSPECTIVE STUDY;

AGED; ANKLE; ANTI-BACTERIAL AGENTS; COMORBIDITY; DAPTOMYCIN; DIABETES MELLITUS; FEMALE; FOOT; HUMANS; MALE; OSTEOMYELITIS; RETROSPECTIVE STUDIES;

EID: 34548337319     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/BLO.0b013e3181123bc5     Document Type: Conference Paper

References (17)

1. Antony SJ, Angelos E, Stratton C. Clinical experience with daptomycin in patients with orthopedic-related infections. Infect Dis Clin Pract. 2006;14:144-149.
2. Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis. 2006;38:133-136.
3. Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2006.
4. Dretler R, Branch T. MRSA knee infection treated successfully with daptomycin after two failed prolonged high-dose courses of vancomycin. Infect Dis Clin Pract. 2005;13:327-329.
5. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Exp Opin Investig Drugs. 2004;13:1159-1169.
6. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug resistant Gram-positive bone and joint infections. Curr Med Res Opin. 2005;21:1923-1926.
7. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285-5287.
8. Lamp KC, Friedrich LV. Clinical experience with Daptomycin (DAP) for the treatment of osteomyelitis in patients with post-therapy follow-up. Abstract No. L-1557. ICAAC, ASM. San Francisco, CA, Sep. 27-30, 2006.
9. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother. 1992;36:2709-2714.
10. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25:1318-1326.
11. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240-245.
12. Luu QN, Buxton TB, Nelson DR, Rissing JP. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis. 1989;8:562-563.
13. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. 1989;33:689-692.
14. Norden CW, Niederriter K. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with LY146032. Infection. 1988;16:27.
15. Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res. 2006;451:34-37.
16. Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother. 2006;572:301-305.
17. Vikram H, Havill NL, Koeth L, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol. 2005;43:5384-5387.